Description: Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.
Home Page: www.herantis.com
Bertel Jungin Aukio 1
Espoo,
02600
Finland
Phone:
358 9222 1195
Officers
| Name | Title |
|---|---|
| Dr. Antti Vuolanto D.Sc. (Tech) | CEO & COO |
| Ms. Tone Kvale | Chief Financial Officer |
| Dr. Henri J. Huttunen | Chief Scientific Officer |
| Ms. Sigrid Booms | Head of Regulatory Affairs & Compliance |
| Ms. Jutta Poutanen | Head of Quality |
| Mr. Jani Koskinen | Head of CMC |
| Ms. Outi Lahdenperä M.D., Ph.D. | Chief Medical Ofcer |
Exchange: HE
Country: FI
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 15.1665 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 13 |